Genentech Fitting Better
By
Brian Lawler
October 16, 2007
|
Genentech (NYSE: DNA) released its third-quarter financial results yesterday. Like an overweight businessman losing pounds and fitting into his suit better, Genentech's previous lofty P/E valuation continues to come down as it boosts its bottom line every quarter, yet has a slightly lower share price for the year.
Genentech continued its streak of double-digit growth in its top and bottom lines in the quarter, with a year-over-year 22% gain in revenue and 22% gain in net income after excluding one-time charges. Importantly, Genentech is managing to keep its non-R&D expenditures in check as its bottom line grew at the same speed as its top line, even though research and development spending was up 38% in the quarter.
Its top drug, cancer treatment Avastin, is still experiencing torrid expansion, as sales of the drug were up 37% year over year, making up for the mediocre 6% growth in Herceptin as it comes under competitive attack from GlaxoSmithKline's (NYSE: GSK) Tykerb.
Dozens of clinical trials have expanded Avastin's uses to include every major type of solid tumor there is. The drug has a PDUFA date of Feb. 23 for its label expansion into first-line metastatic breast cancer. Barring the introduction of small-molecule competitors from Pfizer (NYSE: PFE) or another big pharma, Avastin's growth rate won't be hampered any time soon.
Except for the fact that it doesn't pay a dividend, Genentech is becoming the new Johnson & Johnson (NYSE: JNJ). It continues to post quarter after quarter of double-digit revenue and earnings growth. It peddles biologics, and since there is not yet a good regulatory pathway in the U.S. giving generic-drug makers a chance to produce biogenerics, discount competitors against its top drugs aren't likely to emerge any time soon.
“The Death of the Euro!”…Greece may seem worlds away, but be warned. What happens there next could reshape global finance and rattle your portfolio. On Mar. 22, The Motley Fool’s Tim Hanson heads to Greece to get the story. Follow in real time and hear how best to profit from this historic development (Hanson returned from China in July with a stock that’s up 117%!). Enter email below.